Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Viropro, a developer and manufacturer of biopharmaceutical drugs, has entered into a biosimilar collaboration agreement with Oncobiologics.
Subscribe to our email newsletter
Under the agreement, Viropro will manufacture six monoclonal antibody products, being developed by Oncobiologics, including generic versions of Humira, Rituxan, Avastin, Herceptin, Erbitux and a non-disclosed biotherapeutic used for cancer and immune-disease indications.
The manufactured products will be used for commercialization in more than 70 emerging market countries (excluding China) and Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia.
In addition, both the companies will co-manage Viropro’s Penang, Malaysia Alpha Biologics biomanufacturing subsidiary.
Oncobiologics founder and CEO Pankaj Mohan said the combination of a biologics manufacturing facility and support from the Malaysian Government makes Viropro an ideal partner.
"This unique partnership allows us to bring together technical expertise and quality oversight from the U.S. with a high capability, low cost biologics operation in Malaysia," Mohan added.
The collaboration is planning to launch the first product by late 2014.
Both the companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue run rate of $60-$150m within10 years.